AGP Executive Report
Last update: 8 hours agoCancer Care: A global Phase III trial found that adding HUTCHMED’s targeted drug savolitinib to osimertinib cut the risk of progression or death by 45% for some lung cancer patients whose disease worsened on treatment. Healthcare Workforce: Brigham and Women’s nurses rejected the hospital’s latest contract offer; their union says it wants to resume talks, but a strike remains possible. Primary Care Access: Australia’s share of GPs who bulk bill all patients more than doubled to 26%, but the RACGP warns some people still face higher out-of-pocket costs. Safer Treatment: A DNA test studied in about 6,000 prostate cancer patients may help doctors identify who could avoid more intensive treatment. Patient Safety: A South Korean doctor was fined after a patient died during acupuncture; the court found he failed to respond promptly to signs of distress.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
Pseudo-journalism: Pink-slime
